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The paper by Aspelund et al. [1] reports the potential impact
of allocating individuals to different review intervals in
screening for sight-threatening diabetic retinopathy (STDR)
according to their risk profile. This is an idea which has
been around for some time, given that we can identify some
of the principal risk factors implicated in determining the
risk of STDR over time. Risk engines have also been de-
veloped to estimate the risk of stroke and cardiovascular
disease [2]. The evaluation of the model developed by
Aspelund et al. to determine screening intervals shows that
by reducing the number of screens while still detecting the
same number of cases of STDR, screening can be more cost-
effective. The algorithm has been validated using Danish
data collected over a 20-year period, so the model is all the
more interesting because of this. However, there are a num-
ber of important questions to be considered before wide-
spread implementation.
If we follow the algorithm and the recommendation of
their rescreening schedule, the interval between screens
could be as long as 60 months. However, the risk status of
some patients may change in the interim in terms of blood
pressure, blood-sugar control and background diabetic reti-
nopathy (DR). If it is indeed true that risk of complications
can be reliably predicted over such a long period, then
patients are remarkably true to form. One large cohort study
[3] did find that the incidence of retinopathy after 6 years
was associated with glycaemia and blood pressure at base-
line, although the role of intensive blood-sugar control in
prevention of retinopathy is still debated [4].
A population-based study from Norwich, UK which in-
vestigated patients managed in general practice between
1990 and 2006 [5] reported that screening intervals of 18–
24 months compared to 12–18 months were not associated
with a higher risk of development of STDR. However, there
was a 60% increase in likelihood of STDR being detected if
the screen interval was more than 2 years. Both Iceland and
Sweden use extended screening intervals for people at low
risk, but these countries have relatively small populations,
high levels of funding, and compliance with care. Else-
where, primary care may not be so reliable, or even absent,
and systemic risk factors less well-controlled. In applying
the algorithm to another country, we may probably need to
take account of not just attendance rates but also different
baselines for risk factors and incidence of STDR.
The English National Screening Programme for DR has
been reluctant to change to a variable rescreening schedule
for a number of practical reasons. The rate of non-
attendance for screening can be as high as 30%. Local health
providers are responsible for keeping track of the patients,
and a longer screening interval adds to the difficulty.
Patients may move or default. If any patient comes to harm
and develops complications because the system failed to
remind them in a repeated and timely fashion, there may
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ensuringafail-safefollow-upsystem,althoughtheprocedures
of this may vary between countries. While having an eye
examination at the same time every year might help in adher-
ing to the schedule, more frequent screening such as every
6 monthscould beseenasanunnecessary inconvenience.The
effectiveness of a variable schedule for DR within a central-
ised screening system requires careful assessment.
The generalisability of the model and longer screening
intervals therefore remains unclear. A new screening
programme might adopt the concept of risk stratification
but modify the details. For example, in the case of Hong
Kong, we have decided to use the published algorithm
rather than a default annual recall, and we stratify patients'
risk, inviting some to come at 6 months but with no assigned
interval longer than 2 years. In this way, we may achieve a
good compromise, i.e., for those with high risk, we are more
likely to detect progression and provide intervention, while
seeing everyone within 2 years means that all patients know
they have to be seen again, making it possibly less likely
that they will fall out of the system. However, reducing the
length of the screening intervals for lower risk cases will
involve more screening episodes, and less than the 59%
saving that adopting the full algorithm might achieve.
In a developing country such as China, where health care
provision is non-homogenous and the wealth gap large, a
variation of the algorithm may be even more beneficial if it
can be implemented safely. For example, screening for DR
once every 3–5 years, referring all STDR to an ophthalmol-
ogist and, at the same time, referring all high-risk patients
without STDR to community clinics for better management
of blood pressure and glycaemic control might even achieve
more than reduction of blindness, if these important cardio-
vascular risk factors are reduced. While screening on an
annual basis is likely to be impossible in such circumstan-
ces, a variable interval with a longer time between screens
might detect a sufficient proportion of the STDR cases in a
timely manner, and also achieve reduction in overall risk in
a substantial proportion of the non-STDR cases.
The risk algorithm as applied by Aspelund et al. poten-
tially achieves savings in costs of screening by shifting the
risk of STDR away from those at higher risk but onto those
at lower risk, so that the risk of the different groups becomes
more similar. This should focus us on equity and the need to
ensure that every other means of reducing the risk of the
higher risk cases, such as better risk factor control, is being
undertaken. It also focuses us on the protocols for ensuring
compliance — to more frequent screening in the case of the
higher risk groups and longer screening intervals in low risk
cases. It reminds us that, especially in countries with a
mixed private/public healthcare system, a screening
programme is unlikely to achieve full population coverage,
and many of those missed will be the higher risk cases. It
raises the question of what level of risk of STDR is accept-
able in both developed and developing economies.
As we wrestle with the rapid increase in diabetes and the
consequent rising prevalence of DR, innovative solutions
such as that proposed in the Apselund model merit close
study. Real-life evidence and results of further trials will be
essential to underpin screening practice, especially for youn-
ger patients and those at higher risk, and this evidence needs
to be developed for the implementation in widely ranging
health care models throughout the world. There are still
many questions to answer.
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